# Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

> **NCT01309698** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Vildagliptin (LAF237)
- **DRUG:** Voglibose
- **DRUG:** Vildagliptin and Voglibose

## Key facts

- **NCT ID:** NCT01309698
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-04
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01309698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01309698, "Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01309698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*